Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The American Cancer Society has updated its prostate cancer screening guidelines, recommending PSA testing every 2 years for average-risk men aged 50–69 and annually starting at 45 for high-risk groups. Backed by 23 years of trial data showing a 13% reduction in prostate cancer deaths, the new guidance also leans on advances like MRI-guided diagnostics and active surveillance to reduce overtreatment. But experts warn the recommendations will fall short without affordable, accessible follow-up care.
The American Cancer Society (ACS) has issued updated prostate cancer screening recommendations, calling for PSA blood tests every 2 years for average-risk men aged 50–69, and annually starting at 45 for Black men and those with a strong family history. The shift is backed by a landmark 23-year European randomized trial showing that repeated PSA screening reduced prostate cancer mortality by 13% — roughly two fewer deaths per 1,000 men screened.
What makes this update more compelling than past guidance is the growing toolkit to reduce screening's downsides. MRI-directed biopsy cut detection of clinically insignificant cancers by 57% in one trial. Transperineal biopsy slashed infection rates to near zero. Active surveillance for low-risk cancers showed just 0.1% cancer mortality at 10 years. And precision radiation and nerve-sparing surgical techniques are meaningfully improving quality of life after treatment.
Still, better tools alone aren't enough — health systems must close the access gap.
Key Takeaways:
Why it matters: Updated guidelines only deliver on their promise if patients can actually afford and access the full diagnostic pathway. Without system-level changes in coverage, referral infrastructure, and surveillance support, the benefits of improved screening tools will remain out of reach for many — especially Black men, who face higher risk but remain underrepresented in the evidence base.